Management of primary osteoporosis

被引:16
作者
Body, JJ
机构
[1] Free Univ Brussels, Inst Jules Bordet, Dept Med, Clin Endocrinol & Bone Dis, Brussels, Belgium
[2] Free Univ Brussels, Inst Jules Bordet, Dept Med, Support Care Clin, Brussels, Belgium
关键词
D O I
10.1179/acb.2002.054
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although there is a great need for better therapeutic approaches to the patient who presents with a fracture, osteoporotic fractures will remain a condition that is more amenable to prevention than treatment. Hormone replacement therapy (HRT) is still considered by many the mainstay for the prevention and the treatment of posrmenopausal osteoporosis. However, there are several controversies regarding HRT, especially the duration of treatment and the risks/benefits ratio. Recent studies have challenged the assumption that HRT conveys real long-term beneficial effects. Raloxifene or other "selective estrogen receptor modulators" (SERMs) should progressively replace HRT in elderly women. Bisphosphonates have demonstrated a clearcut efficacy in the treatment of osteoporosis. Alendronate and risedronate have been the most extensively studied bisphosphonates under randomized controlled trials conditions. Both agents can reduce the risk of vertebral and hip fractures by one-fourth to one-half. However, oral bisphosphonates are not without gastro-intestinal toxicity and strict adherence to constraining therapeutic schemes is mandatory. Intermittent treatments are alredy in use. Weekly alendronate is as efficient as daily therapy and improves treatment compliance. Newer more potent bisphosphonates, such as oral ibandronate or intravenous zoledronic acid, will allow much less frequent administration. The anti-fracture efficacy of yearly zoledronic acid infusions is thus currently tested. On the other hand, bone-forming agents, such as daily subcutaneous injections of teriparatide (rhPTH 1-34) offer exciting perspectives for the treatment of severe osteoporosis despite the complexity of such therapy.
引用
收藏
页码:277 / 283
页数:7
相关论文
共 34 条
[1]   Raloxifene and cardiovascular events in osteoporotic postmenopausal women - Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial [J].
Barrett-Connor, E ;
Grady, D ;
Sashegyi, A ;
Anderson, PW ;
Cox, DA ;
Hoszowski, K ;
Rautaharju, P ;
Harper, KD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (07) :847-857
[2]   Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].
Black, DM ;
Cummings, SR ;
Karpf, DB ;
Cauley, JA ;
Thompson, DE ;
Nevitt, MC ;
Bauer, DC ;
Genant, HK ;
Haskell, WL ;
Marcus, R ;
Ott, SM ;
Torner, JC ;
Quandt, SA ;
Reiss, TF ;
Ensrud, KE .
LANCET, 1996, 348 (9041) :1535-1541
[3]  
Body JJ, 2002, BONE, V30, p75S
[4]  
BODY JJ, IN PRESS J CLIN ENDO
[5]  
BODY JJ, 1998, OSTEOPOROSIS INT S3, V8, P106
[6]  
BODY JJ, IN PRESS CANCER
[7]   ESTROGEN REPLACEMENT THERAPY AND FRACTURES IN OLDER WOMEN [J].
CAULEY, JA ;
SEELEY, DG ;
ENSRUD, K ;
ETTINGER, B ;
BLACK, D ;
CUMMINGS, SR .
ANNALS OF INTERNAL MEDICINE, 1995, 122 (01) :9-16
[8]   VITAMIN-D(3) AND CALCIUM TO PREVENT HIP-FRACTURES IN ELDERLY WOMEN [J].
CHAPUY, MC ;
ARLOT, ME ;
DUBOEUF, F ;
BRUN, J ;
CROUZET, B ;
ARNAUD, S ;
DELMAS, PD ;
MEUNIER, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (23) :1637-1642
[9]   A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study [J].
Chesnut, CH ;
Silverman, S ;
Andriano, K ;
Genant, H ;
Gimona, A ;
Harris, S ;
Kiel, D ;
LeBoff, M ;
Maricic, M ;
Miller, P ;
Moniz, C ;
Peacock, M ;
Richardson, P ;
Watts, N ;
Baylink, D .
AMERICAN JOURNAL OF MEDICINE, 2000, 109 (04) :267-276
[10]   Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs [J].
Cummings, SR ;
Karpf, DB ;
Harris, F ;
Genant, HK ;
Ensrud, K ;
LaCroix, AZ ;
Black, DM .
AMERICAN JOURNAL OF MEDICINE, 2002, 112 (04) :281-289